Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04614753 · ClinicalTrials.gov registry record · NA

Dealcoholized Muscadine Wine and Skin Health in Women

A NA study, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT04614753: Completed NA study, sponsored by University of Florida.

NCT04614753 is a NA study that has completed, run by University of Florida. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04614753, a NA study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

The objective of this clinical trial is to determine the activity of dealcoholized muscadine wine to alleviate oxidative stress, inflammation, skin photoaging, and alter gut microbiome in women 40-67 years of age. The investigators hypothesize that dealcoholized muscadine wine daily for 42 days will significantly alleviate oxidative stress, inflammation, skin photoaging, and alter the gut microbiome in women compared to drinking sugar water.

Primary Outcome

Irradiation will be applied to dorsal skin (back, scapular region not typically exposed to the sun) with 2 times of minimal erythema dose using an FDA approved UVB phototherapy light and a UV light meter. At each time point on day 0 and 29, skin color will be measured before and 24 h after irradiation. Skin color will be evaluated by a colorimeter.

Interventions

  • OTHER Control Beverage
  • OTHER Dealcoholized Muscadine Wine

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2020-10-10
Est. Completion 2024-10-07
Phase NA
University of Florida

1,106 total trials

What the finished NCT04614753 record still lists

NCT04614753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Control Beverage is the first listed.

NCT04614753 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04614753 about?

NCT04614753 is a clinical study titled "Dealcoholized Muscadine Wine and Skin Health in Women". The objective of this clinical trial is to determine the activity of dealcoholized muscadine wine to alleviate oxidative stress, inflammation, skin photoaging, and alter gut microbiome in women 40-67 years of age. The investigators hypothesize that dealcoholized muscadine wine daily for 42 days will...

What is the current status of trial NCT04614753?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2020-10-10. Estimated completion is 2024-10-07.

What interventions are being tested in trial NCT04614753?

The interventions under investigation include: Control Beverage (OTHER), Dealcoholized Muscadine Wine (OTHER).

Who is sponsoring clinical trial NCT04614753?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04614753's enrollment target sits among peer trials

20 1768th of 2000 higher than 140 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04614753, the US trial registry maintained by the National Library of Medicine. NCT04614753 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.